Bio Key International Inc 8-K, filed Jan 11, 2024
Bio Key International Inc (BKYI)
8-K
2024-01-11
For: 2024-01-08
View Original
Added on
April 05, 2026
About this 8-K
Bio Key International Inc filed this 8-K on January 11, 2024, reporting on events of January 8, 2024.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2024
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
(732 ) 359-1100
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
|
Emerging growth company
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously reported on January 12, 2023 and July 12, 2023, BIO-key International, Inc. (the “Company”) received notices from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
As of January 5, 2024, the closing bid price of the Company’s common stock was greater than $1.00 per share for 10 consecutive business days. By letter dated January 8, 2024, Nasdaq notified the Company that based on the forgoing, Nasdaq determined that the Company is now in compliance with the Bid Price Rule and that the matter has been closed. Based on the forgoing, the Company is currently in compliance with the Bid Price Rule.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIO-KEY INTERNATIONAL, INC.
|
|||
|
Date: January 11, 2024
|
|||
|
By:
|
/s/ Cecilia C. Welch
|
||
|
Cecilia C. Welch
|
|||
|
Chief Financial Officer
|
|||